SG10201907501QA - Antibodies and assays for detection of folate receptor 1 - Google Patents
Antibodies and assays for detection of folate receptor 1Info
- Publication number
- SG10201907501QA SG10201907501QA SG10201907501QA SG10201907501QA SG 10201907501Q A SG10201907501Q A SG 10201907501QA SG 10201907501Q A SG10201907501Q A SG 10201907501QA SG 10201907501Q A SG10201907501Q A SG 10201907501QA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- folate receptor
- assays
- detection
- receptor
- Prior art date
Links
- 102000010451 Folate receptor alpha Human genes 0.000 title abstract 3
- 108050001931 Folate receptor alpha Proteins 0.000 title abstract 3
- 238000003556 assay Methods 0.000 title abstract 3
- 238000001514 detection method Methods 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 102000006815 folate receptor Human genes 0.000 abstract 1
- 108020005243 folate receptor Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
ANTIBODIES AND ASSAYS FOR DETECTION OF FOLATE RECEPTOR 1 The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided. No suitable fig.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361872407P | 2013-08-30 | 2013-08-30 | |
US201361875475P | 2013-09-09 | 2013-09-09 | |
US201461940184P | 2014-02-14 | 2014-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201907501QA true SG10201907501QA (en) | 2019-10-30 |
Family
ID=52587498
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201907501Q SG10201907501QA (en) | 2013-08-30 | 2014-08-29 | Antibodies and assays for detection of folate receptor 1 |
SG10202100275TA SG10202100275TA (en) | 2013-08-30 | 2014-08-29 | Antibodies and assays for detection of folate receptor 1 |
SG11201601037YA SG11201601037YA (en) | 2013-08-30 | 2014-08-29 | Antibodies and assays for detection of folate receptor 1 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202100275TA SG10202100275TA (en) | 2013-08-30 | 2014-08-29 | Antibodies and assays for detection of folate receptor 1 |
SG11201601037YA SG11201601037YA (en) | 2013-08-30 | 2014-08-29 | Antibodies and assays for detection of folate receptor 1 |
Country Status (28)
Country | Link |
---|---|
US (5) | US9637547B2 (en) |
EP (2) | EP3925980A1 (en) |
JP (4) | JP2016536330A (en) |
KR (3) | KR102428492B1 (en) |
CN (2) | CN113150145A (en) |
AU (3) | AU2014312086B2 (en) |
BR (1) | BR112016003665B1 (en) |
CA (2) | CA3222465A1 (en) |
CY (1) | CY1124428T1 (en) |
DK (1) | DK3038650T3 (en) |
ES (1) | ES2883191T3 (en) |
HK (1) | HK1222402A1 (en) |
HR (1) | HRP20211317T1 (en) |
HU (1) | HUE055856T2 (en) |
IL (2) | IL244061B (en) |
LT (1) | LT3038650T (en) |
MX (2) | MX371496B (en) |
MY (1) | MY176282A (en) |
NZ (1) | NZ717140A (en) |
PL (1) | PL3038650T3 (en) |
PT (1) | PT3038650T (en) |
RS (1) | RS62240B1 (en) |
RU (1) | RU2725825C2 (en) |
SG (3) | SG10201907501QA (en) |
SI (1) | SI3038650T1 (en) |
UA (1) | UA120166C2 (en) |
WO (1) | WO2015031815A2 (en) |
ZA (1) | ZA201907806B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI504408B (en) | 2010-02-24 | 2015-10-21 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
KR20200039843A (en) | 2011-04-01 | 2020-04-16 | 이뮤노젠 아이엔씨 | Methods for increasing efficacy of folr1 cancer therapy |
KR20150046316A (en) | 2012-08-31 | 2015-04-29 | 이뮤노젠 아이엔씨 | Diagnostic assays and kits for detection of folate receptor 1 |
EP3925980A1 (en) | 2013-08-30 | 2021-12-22 | ImmunoGen, Inc. | Antibodies and assays for detection of folate receptor 1 |
DK3055332T3 (en) * | 2013-10-08 | 2019-12-09 | Immunogen Inc | ANTI-FOLR1 immunoconjugate-DOSAGE REGIMES |
MA40415A (en) * | 2014-09-03 | 2016-03-10 | Immunogen Inc | Conjugates comprising cell-binding agents and cytotoxic agents |
CN107428837A (en) * | 2015-04-22 | 2017-12-01 | 免疫医疗公司 | Circulate separation, detection, diagnosis and/or the identification of the positive cancer cells of TROP 2 |
KR20180053319A (en) | 2015-09-17 | 2018-05-21 | 이뮤노젠 아이엔씨 | Therapeutic combinations comprising an anti-FOLR1 immunoconjugate |
WO2019050935A1 (en) * | 2017-09-05 | 2019-03-14 | Immunogen, Inc. | Methods for detection of folate receptor 1 in a patient sample |
CN108152189B (en) * | 2017-12-06 | 2020-06-05 | 浙江大学 | Quantitative detection method for sperm surface clouding protein 1 |
SG11202007494TA (en) | 2018-03-13 | 2020-09-29 | Phanes Therapeutics Inc | Anti-folate receptor 1 antibodies and uses thereof |
EA038215B1 (en) * | 2018-06-09 | 2021-07-26 | Федеральное государственное бюджетное научное учреждение "Федеральный научный центр исследований и разработки иммунобиологических препаратов им. М.П. Чумакова РАН" | Method for quantitative determination of yellow fever virus antigen by enzyme immunoassay using specific yolk antibodies and biotin-labelled detector antibodies |
US11396543B2 (en) | 2019-04-29 | 2022-07-26 | Immunogen, Inc. | Biparatopic FR-α antibodies and immunoconjugates |
FI4103236T3 (en) | 2020-10-27 | 2023-11-09 | Elucida Oncology Inc | Folate receptor targeted nanoparticle drug conjugates and uses thereof |
CN112794911B (en) * | 2021-04-14 | 2021-08-03 | 上海偌妥生物科技有限公司 | Humanized anti-folate receptor 1 antibody and application thereof |
WO2023116911A1 (en) * | 2021-12-24 | 2023-06-29 | 百奥泰生物制药股份有限公司 | ANTI-FRα ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF |
WO2023170216A1 (en) * | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
CN117700556B (en) * | 2024-02-05 | 2024-04-12 | 苏州百道医疗科技有限公司 | anti-FR alpha mouse monoclonal antibody and application thereof |
Family Cites Families (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2046920B1 (en) | 1969-06-19 | 1974-05-03 | Citizen Watch Co Ltd | |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
AU4434585A (en) | 1985-03-30 | 1986-10-23 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (en) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | METHOD FOR DECODING BINARY SIGNALS AND VITERBI DECODERS AND APPLICATIONS |
US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
JP3040121B2 (en) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | Methods of treating tumor cells by inhibiting growth factor receptor function |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
JPH049249A (en) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | Facing agent spraying machine |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6916605B1 (en) | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ATE158021T1 (en) | 1990-08-29 | 1997-09-15 | Genpharm Int | PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ATE164395T1 (en) | 1990-12-03 | 1998-04-15 | Genentech Inc | METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
ES2202310T3 (en) | 1991-12-13 | 2004-04-01 | Xoma Corporation | METHODS AND MATERIALS FOR THE PREPARATION OF VARIABLE DOMAINS OF MODIFIED ANTIBODIES AND THEIR THERAPEUTIC USES. |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
DK0627940T3 (en) | 1992-03-05 | 2003-09-01 | Univ Texas | Use of immunoconjugates for diagnosis and / or therapy of vascularized tumors |
US20030148406A1 (en) | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5432930A (en) | 1993-09-30 | 1995-07-11 | Eagle Crest Limited | System for accessing cobol data files by generating a dictionary of NF.sup.2 |
NL9302194A (en) | 1993-12-15 | 1995-07-03 | Nidera Handelscompagnie B V | Process for preparing a combined fish product, as well as fish product obtained using this process. |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
DE19526926A1 (en) | 1995-07-24 | 1997-01-30 | Bayer Ag | Process for the production of loaded non-porous carrier materials |
US6828422B1 (en) | 1995-08-18 | 2004-12-07 | Morphosys Ag | Protein/(poly)peptide libraries |
JP4436457B2 (en) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | Protein / (poly) peptide library |
WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US6596850B1 (en) | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
CA2354862A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
WO2001002588A2 (en) | 1999-07-02 | 2001-01-11 | Morphosys Ag | Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
IT1307309B1 (en) | 1999-12-30 | 2001-10-30 | Enea Ente Nuove Tec | STABILIZING PEPTIDES, POLYPEPTIDES AND ANTIBODIES THAT INCLUDE THEM. |
NZ521898A (en) | 2000-03-31 | 2004-11-26 | Purdue Research Foundation | Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response |
DE10037759A1 (en) | 2000-08-03 | 2002-07-04 | Gruenenthal Gmbh | screening process |
ATE400030T1 (en) | 2001-02-19 | 2008-07-15 | Merck Patent Gmbh | METHOD FOR IDENTIFYING T CELL PITOPES AND ITS APPLICATION TO PRODUCING MOLECULES WITH REDUCED IMMUNOGENICITY |
AU2002258518A1 (en) | 2001-03-14 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
WO2002087424A2 (en) | 2001-05-02 | 2002-11-07 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
US7314974B2 (en) | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
WO2003074704A1 (en) | 2002-03-01 | 2003-09-12 | Japan Envirochemicals, Ltd. | Proteins capable of binding to female sex hormones and process for producing the same |
EP2287198A3 (en) | 2002-03-13 | 2011-05-25 | Biogen Idec MA Inc. | Anti-alpha V beta 6 antibodies |
CA2482607C (en) | 2002-04-22 | 2013-06-11 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
BRPI0314038B8 (en) * | 2002-09-06 | 2021-05-25 | Amgen Inc | isolated human antibody, isolated nucleic acid molecule, vector, use of an antibody, and pharmaceutical composition |
AU2003295411A1 (en) | 2002-11-07 | 2004-06-03 | Celltech R & D | Human monoclonal antibodies to heparanase |
EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
US20080131366A1 (en) | 2003-03-17 | 2008-06-05 | Manohar Ratnam | Folate Receptor Gene Modulation For Cancer Diagnosis And Therapy |
US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
CA2897608C (en) | 2003-05-09 | 2018-07-31 | Duke University | Cd20-specific antibodies and methods employing same |
KR101424624B1 (en) | 2003-05-14 | 2014-07-31 | 이뮤노젠 아이엔씨 | Drug Conjugate Composition |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
AU2004253953A1 (en) | 2003-07-02 | 2005-01-13 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7622112B2 (en) | 2003-12-05 | 2009-11-24 | Jody Berry | Anti-SARS monoclonal antibodies |
EP3101034A1 (en) | 2004-02-12 | 2016-12-07 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
EP2259063B1 (en) | 2004-04-27 | 2012-05-23 | Galapagos N.V. | Compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts |
CA2581208A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
AU2005306997B2 (en) | 2004-10-25 | 2012-07-05 | Merck Sharp & Dohme Corp. | Anti-ADDL antibodies and uses thereof |
CA2595171C (en) | 2004-12-21 | 2015-03-17 | Monsanto Technology Llc | Transgenic plants with enhanced agronomic traits |
US20090087478A1 (en) * | 2004-12-27 | 2009-04-02 | Progenics Pharmaceuticals (Nevada), Inc. | Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them |
BRPI0518994A2 (en) | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | br3-binding antibodies or polypeptides, their uses and liquid formulations |
EP2153848A3 (en) | 2005-01-27 | 2010-07-21 | The Regents of the University of California | Therapeutic monoclonal antibodies that neutralize botulinium neurotoxins |
US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
DK1866339T3 (en) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-binding molecules and their applications |
CA2602585A1 (en) | 2005-03-30 | 2006-10-05 | Purdue Research Foundation | Method for cancer prognosis using cellular folate vitamin receptor quantification |
US20060239910A1 (en) | 2005-04-22 | 2006-10-26 | Morphotek Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
EP1888639A1 (en) | 2005-05-12 | 2008-02-20 | Oncotherapy Science, Inc. | Methods for damaging cells using effector function of anti-dsc2 antibody |
AU2006249087B2 (en) | 2005-05-20 | 2012-05-17 | Lonza Biologics Plc | High-level expression of recombinant antibody in a mammalian host cell |
US20090285795A1 (en) | 2005-05-24 | 2009-11-19 | Villoo Morawala Patell | Method for the Production of a Monoclonal Antibody to CD20 for the Treatment of B-Cell Lymphoma |
EP1904183B1 (en) | 2005-07-05 | 2014-10-15 | Purdue Research Foundation | Pharmaceutical composition for the treatment of osteoarthritis |
US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
WO2007022416A2 (en) | 2005-08-18 | 2007-02-22 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
JP4938263B2 (en) * | 2005-08-19 | 2012-05-23 | 独立行政法人農業生物資源研究所 | Method for inhibiting cytosolic protein function using single-chain antibody and use thereof |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP1931710B1 (en) * | 2005-08-31 | 2017-01-18 | Merck Sharp & Dohme Corp. | Engineered anti-il-23 antibodies |
JP5376948B2 (en) | 2005-09-13 | 2013-12-25 | ナショナル リサーチ カウンシル オブ カナダ | Methods and compositions for modulating tumor cell activity |
AU2006304605A1 (en) | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
ES2526079T3 (en) | 2005-12-20 | 2015-01-05 | Sbi Biotech Co., Ltd. | Anti-ILT7 antibody |
WO2007109749A2 (en) * | 2006-03-21 | 2007-09-27 | Wyeth | Methods for preventing and treating amyloidogenic diseases |
WO2007143561A1 (en) | 2006-06-01 | 2007-12-13 | Mayo Foundation For Medical Education And Research | Immunity to folate receptors |
JP5564249B2 (en) | 2006-06-23 | 2014-07-30 | アレシア・バイオセラピューティクス・インコーポレーテッド | Polynucleotide and polypeptide sequences involved in cancer |
US7910702B2 (en) | 2006-07-28 | 2011-03-22 | The Governors Of The University Of Alberta | Recombinant antibodies to sclerotinia antigens |
JP5244103B2 (en) | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | Organ-specific protein and method of use thereof |
HUE052220T2 (en) | 2006-09-08 | 2021-04-28 | Abbvie Bahamas Ltd | Interleukin -13 binding proteins |
EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
MX2009003738A (en) | 2006-10-12 | 2009-07-17 | Forerunner Pharma Res Co Ltd | Diagnosis and treatment of cancer using anti-ereg antibody. |
WO2008072723A1 (en) | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | ANTI-Claudin-3 MONOCLONAL ANTIBODY, AND TREATMENT AND DIAGNOSIS OF CANCER USING THE SAME |
MX2009006659A (en) | 2006-12-20 | 2009-10-12 | Mmr Information Systems Inc | Antibodies and methods for making and using them. |
US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
EP2129402A2 (en) | 2007-02-16 | 2009-12-09 | KTB Tumorforschungsgesellschaft mbH | Receptor and antigen targeted prodrug |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
CN103396489A (en) * | 2007-02-23 | 2013-11-20 | 默沙东公司 | Engineered anti-IL-23p19 antibodies |
US7915368B2 (en) * | 2007-05-23 | 2011-03-29 | Bridgestone Corporation | Method for making alkoxy-modified silsesquioxanes |
WO2008145136A1 (en) | 2007-05-30 | 2008-12-04 | Aarhus Universitet | Stat3 inactivation by inhibition of the folate receptor pathway |
RU2523909C2 (en) | 2007-06-25 | 2014-07-27 | Эндосайт, Инк. | Conjugates, containing hydrophilic spacers of linkers |
CN101139613B (en) | 2007-08-01 | 2011-06-08 | 姜荣锡 | Antineoplastic dibasic polypeptide and application and preparation method thereof |
AU2008334912B8 (en) * | 2007-12-12 | 2013-10-24 | Pincell Srl | Remedies for Pemphigus Containing Anti Fas Ligand antibodies |
PL2227549T3 (en) | 2007-12-21 | 2015-12-31 | Novartis Ag | Selection system for eukaryotic cell culture based on a membrane-bound folate receptor gene |
SG187457A1 (en) | 2008-01-11 | 2013-02-28 | Univ Tokyo | Anti-cldn6 antibody |
WO2009092010A1 (en) | 2008-01-18 | 2009-07-23 | Gagnon Peter S | Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography |
JP5470817B2 (en) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | Battery electrode, battery using the same, and manufacturing method thereof |
WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
RU2487877C2 (en) | 2008-04-30 | 2013-07-20 | Иммьюноджен, Инк. | Potent conjugates and hydrophilic cross-linking agents (linkers) |
JP5769616B2 (en) | 2008-04-30 | 2015-08-26 | イミュノジェン・インコーポレーテッド | Crosslinkers and their use |
US8383351B2 (en) | 2008-06-11 | 2013-02-26 | Oxford Brookes University | Antibody to inhibin/ activin β-B subunit |
NZ592255A (en) | 2008-09-17 | 2013-07-26 | Endocyte Inc | Folate receptor binding conjugates of antifolates |
US20100092470A1 (en) | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
CN101440130B (en) | 2008-11-21 | 2011-07-27 | 中国人民解放军第四军医大学 | Variable regions of heavy chain and light chain of antihuman IL-13R alpha 2 monoclonal antibody |
RS58566B1 (en) | 2008-12-19 | 2019-05-31 | Medicis Pharmaceutical Corp | Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis |
ES2557914T3 (en) | 2009-03-24 | 2016-01-29 | Biocept, Inc. | Devices and methods of cell capture and analysis |
EP2462161B1 (en) | 2009-08-06 | 2017-03-08 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
JP2013507115A (en) * | 2009-10-09 | 2013-03-04 | サノフイ | Polypeptides for binding to "terminal glycation end product receptors" and compositions and methods comprising them |
WO2011100398A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc. | Cd20 antibodies and uses thereof |
TWI504408B (en) | 2010-02-24 | 2015-10-21 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
BR112012022044A2 (en) * | 2010-03-24 | 2020-08-25 | Genentech Inc | ''antibody, immunoconjugate, pharmaceutical formulation, antibody use, treatment method, isolated bispecific antibody and host cell''. |
RU2013122843A (en) | 2010-10-20 | 2014-11-27 | Морфотек, Инк. | Glycoforms of Antibodies Against Folate Alpha Receptor |
CA2816991C (en) | 2010-11-05 | 2020-06-09 | Morphotek Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
US20120259100A1 (en) | 2011-03-29 | 2012-10-11 | Immunogen, Inc. | Process for manufacturing conjugates of improved homogeneity |
EA201991268A3 (en) | 2011-03-29 | 2020-01-31 | Иммуноджен, Инк. | OBTAINING MAYTANSINOID-ANTIBODIES CONJUGATES IN ONE-STEP METHOD |
KR20200039843A (en) | 2011-04-01 | 2020-04-16 | 이뮤노젠 아이엔씨 | Methods for increasing efficacy of folr1 cancer therapy |
WO2012138749A1 (en) | 2011-04-04 | 2012-10-11 | Immunogen, Inc. | Methods for decreasing ocular toxicity of antibody drug conjugates |
WO2012145112A2 (en) | 2011-04-18 | 2012-10-26 | Immunogen, Inc. | Novel maytansinoid derivatives with sulfoxide linker |
EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
RS56985B1 (en) | 2011-07-15 | 2018-05-31 | Eisai R&D Man Co Ltd | Anti-folate receptor alpha antibodies and uses thereof |
KR20150046316A (en) | 2012-08-31 | 2015-04-29 | 이뮤노젠 아이엔씨 | Diagnostic assays and kits for detection of folate receptor 1 |
WO2014055842A1 (en) | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Process for preparing stable antibody maytansinoid conjugates |
JP6136279B2 (en) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | Rolling bearing device |
TWI503850B (en) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | Over-current protection device |
EP2997044A4 (en) | 2013-05-14 | 2017-03-22 | ImmunoGen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
WO2015026909A2 (en) | 2013-08-23 | 2015-02-26 | Nuclea Biotechnologies, Inc. | Msia-srm assay for biomarker analysis |
EP3925980A1 (en) | 2013-08-30 | 2021-12-22 | ImmunoGen, Inc. | Antibodies and assays for detection of folate receptor 1 |
TWI510996B (en) | 2013-10-03 | 2015-12-01 | Acer Inc | Methods for controlling a touch panel and portable computers using the same |
DK3055332T3 (en) | 2013-10-08 | 2019-12-09 | Immunogen Inc | ANTI-FOLR1 immunoconjugate-DOSAGE REGIMES |
WO2015149018A1 (en) | 2014-03-28 | 2015-10-01 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
KR20170027805A (en) | 2014-07-01 | 2017-03-10 | 익스프레션 패톨로지, 인크. | Srm assays to chemotherapy targets |
SG11201701328XA (en) | 2014-09-02 | 2017-03-30 | Immunogen Inc | Methods for formulating antibody drug conjugate compositions |
KR20180053319A (en) | 2015-09-17 | 2018-05-21 | 이뮤노젠 아이엔씨 | Therapeutic combinations comprising an anti-FOLR1 immunoconjugate |
EP3165928B1 (en) | 2015-11-06 | 2019-01-09 | Promise Advanced Proteomics | A method for quantifying anti-tnf antibodies |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
WO2019050935A1 (en) | 2017-09-05 | 2019-03-14 | Immunogen, Inc. | Methods for detection of folate receptor 1 in a patient sample |
SG11202001401TA (en) | 2017-09-22 | 2020-04-29 | Immunogen Inc | Separation of triple-light chain antibodies using cation exchange chromatography |
KR20200108843A (en) | 2018-01-12 | 2020-09-21 | 이뮤노젠 아이엔씨 | Antibody drug conjugation, purification, and formulation method |
US11396543B2 (en) | 2019-04-29 | 2022-07-26 | Immunogen, Inc. | Biparatopic FR-α antibodies and immunoconjugates |
-
2014
- 2014-08-29 EP EP21175678.8A patent/EP3925980A1/en active Pending
- 2014-08-29 JP JP2016537910A patent/JP2016536330A/en active Pending
- 2014-08-29 NZ NZ717140A patent/NZ717140A/en unknown
- 2014-08-29 KR KR1020167008349A patent/KR102428492B1/en active IP Right Grant
- 2014-08-29 ES ES14839399T patent/ES2883191T3/en active Active
- 2014-08-29 RU RU2016109642A patent/RU2725825C2/en active
- 2014-08-29 KR KR1020237033676A patent/KR20230145514A/en active IP Right Grant
- 2014-08-29 MX MX2016002537A patent/MX371496B/en active IP Right Grant
- 2014-08-29 US US14/473,828 patent/US9637547B2/en active Active
- 2014-08-29 SI SI201431868T patent/SI3038650T1/en unknown
- 2014-08-29 CN CN202110062804.4A patent/CN113150145A/en active Pending
- 2014-08-29 EP EP14839399.4A patent/EP3038650B1/en active Active
- 2014-08-29 IL IL244061A patent/IL244061B/en unknown
- 2014-08-29 MY MYPI2016000388A patent/MY176282A/en unknown
- 2014-08-29 DK DK14839399.4T patent/DK3038650T3/en active
- 2014-08-29 CN CN201480054040.2A patent/CN105814079B/en active Active
- 2014-08-29 PL PL14839399T patent/PL3038650T3/en unknown
- 2014-08-29 HU HUE14839399A patent/HUE055856T2/en unknown
- 2014-08-29 RS RS20211028A patent/RS62240B1/en unknown
- 2014-08-29 UA UAA201602669A patent/UA120166C2/en unknown
- 2014-08-29 KR KR1020227026363A patent/KR102585409B1/en active IP Right Grant
- 2014-08-29 BR BR112016003665-4A patent/BR112016003665B1/en active IP Right Grant
- 2014-08-29 CA CA3222465A patent/CA3222465A1/en active Pending
- 2014-08-29 IL IL293871A patent/IL293871A/en unknown
- 2014-08-29 PT PT148393994T patent/PT3038650T/en unknown
- 2014-08-29 SG SG10201907501Q patent/SG10201907501QA/en unknown
- 2014-08-29 LT LTEP14839399.4T patent/LT3038650T/en unknown
- 2014-08-29 SG SG10202100275TA patent/SG10202100275TA/en unknown
- 2014-08-29 AU AU2014312086A patent/AU2014312086B2/en active Active
- 2014-08-29 CA CA2921975A patent/CA2921975C/en active Active
- 2014-08-29 WO PCT/US2014/053512 patent/WO2015031815A2/en active Application Filing
- 2014-08-29 SG SG11201601037YA patent/SG11201601037YA/en unknown
-
2016
- 2016-02-26 MX MX2020001160A patent/MX2020001160A/en unknown
- 2016-09-06 HK HK16110619.2A patent/HK1222402A1/en unknown
-
2017
- 2017-03-29 US US15/473,008 patent/US10017578B2/en active Active
-
2018
- 2018-06-07 US US16/002,364 patent/US10544230B2/en active Active
- 2018-12-03 JP JP2018226360A patent/JP6983746B2/en active Active
-
2019
- 2019-11-21 ZA ZA2019/07806A patent/ZA201907806B/en unknown
- 2019-12-09 US US16/707,940 patent/US11198736B2/en active Active
-
2020
- 2020-05-28 AU AU2020203507A patent/AU2020203507B2/en active Active
- 2020-11-05 JP JP2020185082A patent/JP2021035968A/en not_active Withdrawn
-
2021
- 2021-08-10 CY CY20211100715T patent/CY1124428T1/en unknown
- 2021-08-16 HR HRP20211317TT patent/HRP20211317T1/en unknown
- 2021-11-10 US US17/523,126 patent/US11932701B2/en active Active
-
2022
- 2022-12-27 JP JP2022210118A patent/JP2023040115A/en active Pending
-
2023
- 2023-03-30 AU AU2023201965A patent/AU2023201965A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020001160A (en) | Antibodies and assays for detection of folate receptor 1. | |
CY1122907T1 (en) | DIAGNOSTIC ASSAYS AND KITS FOR DETECTION OF FOLCINE RECEPTOR 1 | |
ZA202206078B (en) | Anti-cd3 antibodies and methods of use | |
PH12016501618A1 (en) | Anti-dll3 antibodies and drug conjugates for use in melanoma | |
MX2021013467A (en) | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof. | |
PH12015502565B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
PH12016500482A1 (en) | Combination therapy with an anti-ang2 antibody and a cd40 agonist | |
PH12016501644B1 (en) | Binding proteins and methods of use thereof | |
MX2016003129A (en) | Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1. | |
SI3221355T1 (en) | Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists | |
SG10201804338PA (en) | Anti-fcrh5 antibodies | |
MX2015012326A (en) | Anti-crth2 antibodies and their use. | |
IN2014DN05885A (en) | ||
MX2014014376A (en) | Anti-biotin antibodies and methods of use. | |
MX2017007491A (en) | Blood brain barrier receptor antibodies and methods of use. | |
PH12014502399B1 (en) | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy | |
MX357675B (en) | Anti-jagged anitbodies and methods of use. | |
MX2018002467A (en) | Antibodies and assays for detection of cd37. | |
MX2014014381A (en) | Anti-theophylline antibodies and methods of use. | |
MX2016005854A (en) | Neuregulin allosteric anti-her3 antibody. | |
GB201901874D0 (en) | Specific monoclonal antibodies of the antigen m of the human metapneumovirus (HMPV), and use thereof in diagnostic method | |
MY192384A (en) | Anti-cd3 antibodies and methods of use |